[{"id":"dcd9e53d-f4f0-4adb-850a-ee80175c02da","acronym":"","url":"https://clinicaltrials.gov/study/NCT04180371","created_at":"2021-01-20T21:59:42.169Z","updated_at":"2024-07-02T16:35:42.863Z","phase":"Phase 1/2","brief_title":"Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression","source_id_and_acronym":"NCT04180371","lead_sponsor":"BicycleTx Limited","biomarkers":" CD4 • EPHA2","pipe":"","alterations":" ","tags":["CD4 • EPHA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • nuzefatide pevedotin (BT5528)"],"overall_status":"Recruiting","enrollment":" Enrollment 288","initiation":"Initiation: 11/07/2019","start_date":" 11/07/2019","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-07-17"}]